The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer

Cantharidin, one of the active components of mylabris, is believed to have antitumor activity. Cantharidin selectively inhibits protein phosphatase 2A (PP2A), which can repress multiple oncogenic kinases (ERK, JNK, PKC, and NF-κB). Researches in vitro have shown that cantharidin suppresses cell viab...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncogenesis
Autors principals: Xu, Meng-Dan, Liu, Lu, Wu, Meng-Yao, Jiang, Min, Shou, Liu-Mei, Wang, Wen-Jie, Wu, Jing, Zhang, Yan, Gong, Fei-Ran, Chen, Kai, Tao, Min, Zhi, Qiaoming, Li, Wei
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6255842/
https://ncbi.nlm.nih.gov/pubmed/30478299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-018-0102-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars